In recent years, quality management has gained increasing importance in healthcare. The field of pathology in particular relies on smooth-running processes and the capability to provide both patients and clinicians with accurate diagnoses, as the specific treatment depends on it.

The “Qualitätssicherungs-Initiative Pathologie” (“QuIP®“, Quality Assurance Initiative Pathology) is a joint venture initiated between the Deutsche Gesellschaft für Pathologie e.V. (DGP) (German Society of Pathology) and the Bundesverband Deutscher Pathologen e.V. (German Pathologists’ Association). Since 2004, the QuIP has been offering round-robin testing services for histopathological, immunohistological and molecular-pathological methods, which serve as external laboratory controls.

As of 2016, it has performed this task as a private limited liability company (GmbH) in order to streamline central processes that had been outsourced up to this point. This is the legal form in which the QuIP intends to get its accreditation to DIN EN ISO 17043 at the earliest possible date. Our service portfolio of round-robin tests is rounded out by advanced training programmes such as PD-L1 diagnostics, as well as individual post-test debriefings by phone. Our work is supported by so-called lead and panel institutes as well as the QuIP board, which provides scientific advice both to the partners and the executive board.



Tumor Mutational Burden (TMB): QuIP organises a study and liaises with FoCR

TMB has been a hotly debated topic amongst pathologists for some time. Beside many vendors of diagnostic tests, some pharmaceutical companies too, such as BMS and Roche/FMI, have been researching this new marker, the clinical merit of which in terms of reliability and reproducibility has yet to be demonstrated.